Identifying Genomic Mutations of Multiple Primary Lung Cancers by Circulating Tumor DNA

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

45 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-01-31

Study Completion Date

2021-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Targeted next generation sequencing (NGS) provides a promising method for diagnostic purposes by enabling the simultaneous detection of multiple gene mutations. This study is to evaluate the feasibility and application value by using NGS into identifying genomic mutations in multiple or multifocal primary lung cancers in cell-tumor DNA (ctDNA) from surgical patients

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison of Circulating Tumor DNA and Tumor Tissue DNA by Targeted Sequencing in Non-Small Cell Lung Cancer

NCT02645318

Carcinoma, Non-Small-Cell Lung

COMPLETED

Circulating Tumor DNA in Surgical Lung Cancer Patients

NCT03081741

Lung Neoplasms

UNKNOWN

Circulating Tumor DNA Detection in Surveillance of Surgical Lung Cancer Patients

NCT02696525

Carcinoma Non-small-cell Lung Cancer Lung Neoplasms

UNKNOWN

Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study

NCT02907606

Carcinoma Non-small-cell Lung Cancer Lung Neoplasms

UNKNOWN

ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage I NSCLS by NGS

NCT03172156

Non-small Cell Lung Cancer Stage I

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Tumor samples originating from clinically considered multiple or multifocal primary lung cancer patients were available for mutational analysis. DNA and RNA were extracted from fresh tumor tissue or formalin-fixed, paraffin-embedded (FFPE) tissue. A series of cancer-related genomic alterations including single nucleotide variations (SNVs), short insertions and deletions (InDels), copy number variations (CNVs) and gene rearrangements were identified by a comprehensive NGS Panal . High frequency mutations were also identified in blood sample by droplet digital polymerase chain reaction(ddPCR).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carcinoma Non-small-cell Lung Cancer Thoracic Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients must have given written informed consent
* Histopathologically confirmed NSCLC
* Considered multiple or multifocal primary lung cancer by clinical criteria

Exclusion Criteria

* Malignant tumor history within the past 5 years
* Patients who received any treatment prior to resection
* Insufficient tumor tissue or blood sample

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No